Several studies have shown that dapagliflozin increases glucagon secretion and liver metabolism, especially gluconeogenesis, shortly after delivery, decreasing hypoglycemia episodes that can be hazardous or episodes where Empagliflozin is more efficient with its mechanism when given in conjunction with a DPP-4 inhibitor, such as linagliptin, and this further improves glycemic control in an insulin-resistant condition [28]. This evidence concerns the gene DPP4 and Hypoglycemia.